Literature DB >> 11269233

In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.

J M Sierra, J Ruiz, M M Navia, M Vargas, J Vila.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11269233      PMCID： PMC90347          DOI： 10.1128/AAC.45.2.643-644.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Antimicrobial Resistance of Nontyphoidal Salmonella Isolates in Traveler's Diarrhea.

Authors: 
Journal:  J Travel Med       Date:  1995-03-01       Impact factor: 8.490

2.  Tropical and exotic infections. Proceedings of the 5th Liverpool Tropical School Bayer Symposium on Microbial Diseases. 14 February 1998.

Authors:  N J Beeching; C A Hart; B I Duerden
Journal:  J Med Microbiol       Date:  2000-01       Impact factor: 2.472

3.  In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.

Authors:  S Ripa; F Mignini; M Prenna; E Falcioni
Journal:  Drugs Exp Clin Res       Date:  1987

4.  Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania.

Authors:  J Vila; M Vargas; C Casals; H Urassa; H Mshinda; D Schellemberg; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Etiology of traveller's diarrhea in Spanish travellers to developing countries.

Authors:  J Gascon; J Vila; M E Valls; L Ruiz; J Vidal; M Corachán; G Prats; M T Jimenez de Anta
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

6.  In vitro activity and fecal concentration of rifaximin after oral administration.

Authors:  Z D Jiang; S Ke; E Palazzini; L Riopel; H Dupont
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

Authors:  W W Hoover; E H Gerlach; D J Hoban; G M Eliopoulos; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1993-02       Impact factor: 2.803

8.  Campylobacter jejuni as a cause of traveler's diarrhea: clinical features and antimicrobial susceptibility.

Authors:  F Gallardo; J Gascón; J Ruiz; M Corachan; M Jimenez de Anta; J Vila
Journal:  J Travel Med       Date:  1998-03       Impact factor: 8.490

9.  Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.

Authors:  H L DuPont; C D Ericsson; J J Mathewson; E Palazzini; M W DuPont; Z D Jiang; A Mosavi; F J de la Cabada
Journal:  Digestion       Date:  1998 Nov-Dec       Impact factor: 3.216

Review 10.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546
View more
  9 in total

1.  Rifaximin for the treatment of acute infectious diarrhea.

Authors:  Kyoung Sup Hong; Joo Sung Kim
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

2.  Bile acids improve the antimicrobial effect of rifaximin.

Authors:  Charles Darkoh; Lenard M Lichtenberger; Nadim Ajami; Elizabeth J Dial; Zhi-Dong Jiang; Herbert L DuPont
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Escherichia coli Causing Traveler's Diarrhea.

Authors:  Elisabet Guiral; Milene Gonçalves Quiles; Laura Muñoz; Javier Moreno-Morales; Izaskun Alejo-Cancho; Pilar Salvador; Miriam J Alvarez-Martinez; Francesc Marco; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 4.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea.

Authors:  Charles D Ericsson
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

Review 7.  Emerging Aeromonas species infections and their significance in public health.

Authors:  Isoken H Igbinosa; Ehimario U Igumbor; Farhad Aghdasi; Mvuyo Tom; Anthony I Okoh
Journal:  ScientificWorldJournal       Date:  2012-06-04

8.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

Review 9.  Rifaximin therapy of irritable bowel syndrome.

Authors:  Hoonmo L Koo; Saman Sabounchi; David B Huang; Herbert L DuPont
Journal:  Clin Med Insights Gastroenterol       Date:  2012-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.